Journal article
Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group
Abstract
BackgroundProstate cancer that has recurred after local therapy or disseminated distantly is usually treated with androgen deprivation therapy; however, most men will eventually experience disease progression within 12 to 20 months. New data emerging from randomized controlled trials (RCTs) of chemotherapy provided the impetus for a systematic review addressing the following question: which non-hormonal systemic therapies are most beneficial …
Authors
Winquist E; Waldron T; Berry S; Ernst DS; Hotte S; Lukka H
Journal
BMC Cancer, Vol. 6, No. 1,
Publisher
Springer Nature
Publication Date
December 2006
DOI
10.1186/1471-2407-6-112
ISSN
1471-2407